Cargando…

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow

BACKGROUND: Therapeutic cancer vaccination against mutant calreticulin (CALR) in patients with CALR-mutant (CALRmut) myeloproliferative neoplasms (MPN) induces strong T-cell responses against mutant CALR yet fails to demonstrate clinical activity. Infiltration of tumor specific T cells into the tumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holmström, Morten Orebo, Andersen, Morten, Traynor, Sofie, Ahmad, Shamaila Munir, Lisle, Thomas Landkildehus, Handlos Grauslund, Jacob, Skov, Vibe, Kjær, Lasse, Ottesen, Johnny T., Gjerstorff, Morten Frier, Hasselbalch, Hans Carl, Andersen, Mads Hald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470021/ https://www.ncbi.nlm.nih.gov/pubmed/37662956 http://dx.doi.org/10.3389/fimmu.2023.1240678

Ejemplares similares

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
por: Grauslund, Jacob Handlos, et al.
Publicado: (2023)

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
por: Handlos Grauslund, Jacob, et al.
Publicado: (2021)

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals
por: Holmström, Morten O., et al.
Publicado: (2019)

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
por: Hasselbalch, Hans Carl, et al.
Publicado: (2018)

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
por: Klausen, Uffe, et al.
Publicado: (2018)

Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
por: Hasselbalch, Hans Carl, et al.
Publicado: (2023)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
por: Mortensen, Rasmus Erik Johansson, et al.
Publicado: (2023)

Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2022)

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression
por: Carnaz Simões, Ana Micaela, et al.
Publicado: (2022)

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression
por: Simões, Ana Micaela Carnaz, et al.
Publicado: (2022)

Aging, Inflammation, and Comorbidity in Cancers—A General In Silico Study Exemplified by Myeloproliferative Malignancies
por: Ottesen, Johnny T., et al.
Publicado: (2023)

Production and Characterization of Peptide Antibodies to the C-Terminal of Frameshifted Calreticulin Associated with Myeloproliferative Diseases
por: Mughal, Farah Perveen, et al.
Publicado: (2022)

HSC Niche Dynamics in Regeneration, Pre-malignancy, and Cancer: Insights From Mathematical Modeling
por: Pedersen, Rasmus Kristoffer, et al.
Publicado: (2022)

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
por: Kjær, Lasse, et al.
Publicado: (2016)

Novel Insights Into Epigenetic Reprogramming and Destabilization of Pericentromeric Heterochromatin in Cancer
por: Gjerstorff, Morten Frier
Publicado: (2020)

Crosstalk between interferon and interleukin-1 antiviral signaling in cancer cells: implications for immune evasion and therapeutic resistance
por: Gjerstorff, Morten Frier
Publicado: (2023)

Epigenetic targeting of myeloid-derived suppressor cells: time to move into infectious diseases?
por: Gjerstorff, Morten Frier
Publicado: (2023)

Human DREF/ZBED1 is a nuclear protein widely expressed in multiple cell types derived from all three primary germ layers
por: Hansen, Simone Valentin, et al.
Publicado: (2018)

Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
por: Kjær, Lasse, et al.
Publicado: (2023)

Interaction between Polycomb and SSX Proteins in Pericentromeric Heterochromatin Function and Its Implication in Cancer
por: Johansen, Simone, et al.
Publicado: (2020)

A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon‐alpha2
por: Dam, Marc J. B., et al.
Publicado: (2022)

Ectopic Expression of Testis Germ Cell Proteins in Cancer and Its Potential Role in Genomic Instability
por: Nielsen, Aaraby Yoheswaran, et al.
Publicado: (2016)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)

Impact of peptide:HLA complex stability for the identification of SARS-CoV-2-specific CD8(+)T cells
por: Lie-Andersen, Olivia, et al.
Publicado: (2023)

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
por: Vannucchi, A M, et al.
Publicado: (2014)

Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment
por: Ottesen, Johnny T., et al.
Publicado: (2020)

Characterization of T-cell responses against IκBα in cancer patients
por: Munir, Shamaila, et al.
Publicado: (2012)

Inflammation induced PD-L1-specific T cells
por: Munir, Shamaila, et al.
Publicado: (2019)

Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms
por: Ha, Jung-Sook, et al.
Publicado: (2015)

Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers
por: Liisborg, Charlotte, et al.
Publicado: (2022)

Potential of Immunotherapies in Treating Hematological Cancer-Infection Comorbidities—A Mathematical Modelling Approach
por: Ottesen, Johnny T., et al.
Publicado: (2021)

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells
por: Munir, Shamaila, et al.
Publicado: (2013)

Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives
por: Hasselbalch, Hans C., et al.
Publicado: (2020)

Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system
por: Liisborg, Charlotte, et al.
Publicado: (2021)

Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development
por: Andersen, Morten, et al.
Publicado: (2017)

ZBED1 Regulates Genes Important for Multiple Biological Processes of the Placenta
por: Johansen, Simone, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_31ku2d3osb5f2nejt8t07k6bhi